MENOPAUSE PRACTICE QUESTIONS
AND ANSWERS WITH COMPLETE
SOLUTIONS ALREADY PASSED!!!!
Which of the following clinical interventions is recognized as the most highly
effective treatment for alleviating moderate-to-severe hot flashes and night
sweats (vasomotor symptoms) in postmenopausal patients?
A. Systemic estrogen therapy
B. Selective estrogen-receptor modulators (SERMs)
C. Testosterone supplementation
D. Clonidine
✔✔ Answer: A. Systemic estrogen therapy
Rationale: Systemic estrogen therapy remains the clinical gold standard and most
potent therapy for reducing the frequency and severity of hot flashes and night
sweats. Other options like SERMs, clonidine, or testosterone are significantly less
effective for targeted vasomotor symptom relief.
Which of the following cytochrome P450 (CYP) isoenzymes is primarily
responsible for metabolizing both estrogen and medroxyprogesterone?
A. CYP3A4
B. CYP1A2
C. CYP2D6
D. All of the above
✔✔ Answer: A. CYP3A4
Rationale: CYP3A4 is the major hepatic enzyme responsible for the metabolic
breakdown of both estrogens and synthetic progestogens (like
medroxyprogesterone). Because of this shared pathway, drugs that act as strong
inhibitors or inducers of the CYP3A4 enzyme can significantly affect the
circulating blood levels and overall efficacy of hormone therapy.
, Continued vasomotor symptoms in a 52-year-old postmenopausal woman with a
history of hysterectomy receiving 0.3 mg of oral conjugated equine estrogens can
best be managed by:
A. Changing to a SERM
B. Changing to gabapentin
C. Increasing the daily estrogen dose
D. Decreasing the daily estrogen dose
C.
A 54-year-old postmenopausal woman is complaining of vaginal dryness, itching,
and pain with intercourse. She has not had any other problems associated with
menopause and has an intact uterus. Which of the following recommendations is
the best treatment option that balances risks and benefits for the management of
this patient's symptoms?
A. Oral conjugated estrogen + medroxyprogesterone acetate
B. Transdermal estradiol + micronized oral progesterone
C. Intravaginal estrogen cream + oral progestogen
D. Intravaginal estrogen cream
D.
Conjugated equine estrogen therapy alone has demonstrated to significantly
increase the risk of:
AND ANSWERS WITH COMPLETE
SOLUTIONS ALREADY PASSED!!!!
Which of the following clinical interventions is recognized as the most highly
effective treatment for alleviating moderate-to-severe hot flashes and night
sweats (vasomotor symptoms) in postmenopausal patients?
A. Systemic estrogen therapy
B. Selective estrogen-receptor modulators (SERMs)
C. Testosterone supplementation
D. Clonidine
✔✔ Answer: A. Systemic estrogen therapy
Rationale: Systemic estrogen therapy remains the clinical gold standard and most
potent therapy for reducing the frequency and severity of hot flashes and night
sweats. Other options like SERMs, clonidine, or testosterone are significantly less
effective for targeted vasomotor symptom relief.
Which of the following cytochrome P450 (CYP) isoenzymes is primarily
responsible for metabolizing both estrogen and medroxyprogesterone?
A. CYP3A4
B. CYP1A2
C. CYP2D6
D. All of the above
✔✔ Answer: A. CYP3A4
Rationale: CYP3A4 is the major hepatic enzyme responsible for the metabolic
breakdown of both estrogens and synthetic progestogens (like
medroxyprogesterone). Because of this shared pathway, drugs that act as strong
inhibitors or inducers of the CYP3A4 enzyme can significantly affect the
circulating blood levels and overall efficacy of hormone therapy.
, Continued vasomotor symptoms in a 52-year-old postmenopausal woman with a
history of hysterectomy receiving 0.3 mg of oral conjugated equine estrogens can
best be managed by:
A. Changing to a SERM
B. Changing to gabapentin
C. Increasing the daily estrogen dose
D. Decreasing the daily estrogen dose
C.
A 54-year-old postmenopausal woman is complaining of vaginal dryness, itching,
and pain with intercourse. She has not had any other problems associated with
menopause and has an intact uterus. Which of the following recommendations is
the best treatment option that balances risks and benefits for the management of
this patient's symptoms?
A. Oral conjugated estrogen + medroxyprogesterone acetate
B. Transdermal estradiol + micronized oral progesterone
C. Intravaginal estrogen cream + oral progestogen
D. Intravaginal estrogen cream
D.
Conjugated equine estrogen therapy alone has demonstrated to significantly
increase the risk of:
